Predicting chemoradiation response with cervical cancer organoids
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is studying whether lab-grown mini-tumors (called organoids) from your cervical cancer biopsy can predict how well chemoradiation will work. It aims to create a tool to help doctors choose the best treatment for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with cervical cancer (certain types).
- You have a tumor sample from a biopsy or surgery that can be studied.
- You are able to get around and take care of yourself (ECOG score 0-2).
- You have not had certain other cancers or severe autoimmune diseases recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a lab-grown mini-tumor (organoid) from your biopsy to test which chemotherapy drugs work best for your cancer before you have surgery. The goal is to personalize your treatment and improve outcomes.
This trial aims to grow miniature versions of cervical cancer tumors (organoids) from biopsy tissue. It helps researchers learn more about the cancer and potentially find better treatments, without any extra procedures beyond your standard diagnostic biopsy.
This trial tests a type of radiation that adapts to your body changes during treatment for cervical cancer. It aims to improve accuracy and reduce side effects.
This study looks at whether certain imaging tests (like MRI, CT, and PET scans) can predict how well your head and neck cancer responds to a standard treatment of radiation plus the chemotherapy drug cisplatin. If you join, researchers will use your scans and treatment results to help personalize care for future patients.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
This trial studies how the immune system responds to pelvic radiation therapy (with or without chemotherapy) in patients with cervical or other gynecologic cancers. It may help explain why some treatments work better and could lead to better treatments in the future.
Hear when a new Cervical Cancer Treated with Pelvic Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.